AN2 Therapeutics News and Activities

AN2 Therapeutics is a company listed under the stock ticker ANTX (US).

View the org chart displaying its 13 main executives

Most searched biographies at AN2 Therapeutics

• Eric Easom, Chief Executive Officer and Chairman of the Board
• Patricia Martin, Member of Board of Directors
• Lynn Marks, Director

Create your alert
to follow the executive moves at AN2 Therapeutics.

AN2 Therapeutics has 1,918 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Ipsen has announced the acquisition of Memo Therapeutics  (posted on July 1 2026).
• Hanmi has acquired Aptose Biosciences (posted on July 1 2026).
• Zymeworks has announced the acquisition of Theravance Biopharma  (posted on June 29 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by AN2 Therapeutics

• Press Releases | AN2 Therapeutics, Inc
• AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. to its Board of Directors
• AN2 Therapeutics Announces Epetraborole Granted Orphan Drug Designation in the U.S. for the Treatment of Infections Caused by Non-Tuberculous Mycobacteria
• AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole
• AN2 Therapeutics Provides Regulatory Update
• AN2 Therapeutics Launches with $12 Million in Series A
• Latest News | Media Contact | AN2 Therapeutics
• AN2 Therapeutics Closed $80 Million Series B Financing
• View more press releases Close

Social media about AN2 Therapeutics

• AN2 Therapeutics on Wikipedia, Google News & Yahoo Finance
• AN2 Therapeutics on LinkedIn, X (Twitter) & YouTube